MANAGEMENT OF PATIENTS WITH HEMOPHILIA A ON EMICIZUMAB PROPHYLACTIC TREATMENT: RECOMMENDATION FROM RUSSIAN EXPERTS

被引：0

作者：

Andreeva, T. A. ^{[1
]}

Zharkov, P. A. ^{[3
]}

Zozulya, N., I ^{[4
]}

Zorenko, V. Yu ^{[4
]}

Konstantinova, V. N. ^{[1
]}

Lebedev, V. V. ^{[2
]}

Mamaev, A. N. ^{[5
]}

Markova, I., V ^{[6
]}

Petrov, V. Yu ^{[7
]}

Polyanskaya, T. Yu ^{[8
]}

Schiller, E. E. ^{[9
]}

机构：

[1] Hematologist Head City Ctr Treatment Patients, City Polyclin 37, St Petersburg 191186, Russia

[2] Childrens Reg Clin Hosp, Head Childrens Reg Oncohematol Ctr, Minist Hlth Krasnodar Reg, Krasnodar 350007, Russia

[3] Dmitriy Rogachev Natl Med Res Ctr Pediat Hematol, Hematologist Consultat Dept, Pediatrician Short Term Treatment Inpatient Dept, Moscow 117997, Russia

[4] Natl Med Res Ctr Hematol, Head Dept Hemostasis Disorders, Moscow 125167, Russia

[5] Natl Med Res Ctr Hematol, Altai Div, Minist Hlth Russian Federat, Moscow 125167, Russia

[6] Raisa Gorbacheva Mem Res Inst Pediat Oncol Hemato, St Petersburg 1999022, Russia

[7] Morozovskaya Childrens City Clin Hosp, Moscow Hlth Dept, Hematologist Hematol Dept, Moscow 119049, Russia

[8] Natl Res Ctr Hematol, Dept Traumatol & Orthoped, Moscow 125167, Russia

[9] Odintsovo Reg Hosp, Head Children Hematol Dept, Odintsovo 143003, Russia

来源：

GEMATOLOGIYA I TRANSFUZIOLOGIYA | 2022年 / 67卷 / 02期

关键词：

emicizumab; hemophilia; factor VIII; factor VIII inhibitor; BISPECIFIC ANTIBODY; INHIBITORS; BLEEDS;

D O I：

10.35754/0234-5730-2022-67-2-267-280

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction. In 2018 emicizumab was approved in Russia for prophylactic treatment in patients with hemophilia A (HA) with inhibitors and in 2019 for patients with severe HA without inhibitors. A significant amount of data has been accumulated from clinical trials and real-world data, which allow us to resolve most of the questions that hematologists may have when to prescribe emicizumab. Aim - to provide information on the management of patients on emicizumab. Results. The recommendations accumulated the currently available information and world experience in the management of patients receiving emicizumab in order to facilitate decision-making when prescribing and using emicizumab. Information on the use of emicizumab in patients with HA with FVIII inhibitors and severe HA without FVIII inhibitors is presented. Possible complications and measures for their prevention and treatment are presented.

引用

页码：267 / 280

页数：14

共 48 条

[21] Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel
Escuriola-Ettingshausen, Carmen
Auerswald, Gunter
Konigs, Christoph
Kurnik, Karin
Scholz, Ute
Klamroth, Robert
Oldenburg, Johannes
HAEMOPHILIA, 2021, 27 (03) : E305 - E313
[22] Laboratory response to paradigm change in hemophilia treatment How to monitor patients simultaneously treated with emicizumab and factor VIII concentrate?
Lambert, Marjan Shafaati
Bruzelius, Maria
Soutari, Nida Mahmoud Hourani
Ranta, Susanna
Antovic, Jovan P. P.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2023, 61 (12) : E248 - E250
[23] Hemophilia care in China: review of care for 417 hemophilia patients from 11 treatment centers in Shanxi Province
Zhao, Hua
Yang, Linhua
Long, Chao
Guo, Yulin
Wu, Ruihong
Liu, Xiue
Qin, Xiuyu
Liang, Hongzheng
Duan, Zhiguang
EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (04) : 543 - 550
[24] Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives
Pasca, Samantha
JOURNAL OF BLOOD MEDICINE, 2022, 13 : 191 - 199
[25] Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
Collins, P. W.
Blanchette, V. S.
Fischer, K.
Bjorkman, S.
Oh, M.
Fritsch, S.
Schroth, P.
Spotts, G.
Astermark, J.
Ewenstein, B.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) : 413 - 420
[26] From theory to practice: Applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors
Gomperts, Edward D.
Astermark, Jan
Gringeri, Alessandro
Teitel, Jerome
BLOOD REVIEWS, 2008, 22 : S1 - S11
[27] Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE)
Coppola, Antonio
Franchini, Massimo
Castaman, Giancarlo
Santagostino, Elena
Santoro, Cristina
Santoro, Rita Carlotta
Morfini, Massimo
Di Minno, Giovanni
Rocino, Angiola
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2018, 44 (06) : 551 - 560
[28] An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A
Takeyama, Masahiro
Nogami, Keiji
Matsumoto, Tomoko
Noguchi-Sasaki, Mariko
Kitazawa, Takehisa
Shima, Midori
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (04) : 825 - 833
[29] A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab
Batt, Katharine
Schultz, Bob G.
Caicedo, Jorge
Hollenbeak, Christopher S.
Agrawal, Neha
Chatterjee, Sagnik
Bullano, Michael
CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (10) : 1685 - 1693
[30] An algorithmic approach to peripheral artery disease in hemophilia: extrapolation of management principles from noncoagulopathic patients
Fogarty, Patrick F.
Olin, Jeffrey W.
Kessler, Craig M.
Konkle, Barbara A.
Aledort, Louis M.
BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (01) : 23 - 29

← 1 2 3 4 5 →